218 related articles for article (PubMed ID: 1538159)
21. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
22. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
[TBL] [Abstract][Full Text] [Related]
23. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
24. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity.
Picard O; Achour A; Bernard J; Halbreich A; Bizzini B; Boyer V; Desgranges C; Bertho JM; Lachgar A; Polliotti B
J Acquir Immune Defic Syndr (1988); 1992; 5(6):539-46. PubMed ID: 1588488
[TBL] [Abstract][Full Text] [Related]
25. Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines.
De Santis C; Robbioni P; Longhi R; Lopalco L; Siccardi AG; Beretta A; Roberts NJ
J Infect Dis; 1993 Dec; 168(6):1396-403. PubMed ID: 8245524
[TBL] [Abstract][Full Text] [Related]
26. Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial.
Archibald DW; Hebert CA; Sun D; Tacket CO
J Acquir Immune Defic Syndr (1988); 1990; 3(10):954-8. PubMed ID: 2204698
[TBL] [Abstract][Full Text] [Related]
27. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.
Funkhouser A; Clements ML; Slome S; Clayman B; Viscidi R
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):627-32. PubMed ID: 8369168
[TBL] [Abstract][Full Text] [Related]
28. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
29. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
32. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
[TBL] [Abstract][Full Text] [Related]
33. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
Barrett N; Eder G; Dorner F
Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
[TBL] [Abstract][Full Text] [Related]
36. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.
Keefer MC; Bonnez W; Roberts NJ; Dolin R; Reichman RC
J Infect Dis; 1991 Mar; 163(3):448-53. PubMed ID: 1995718
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
39. Autoreactivity in HIV-infected individuals does not increase during vaccination with envelope rgp160.
Lundholm P; Wahren M; Sandström E; Volvovitz F; Wahren B
Immunol Lett; 1994 Jul; 41(2-3):147-53. PubMed ID: 8002030
[TBL] [Abstract][Full Text] [Related]
40. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160.
Tacket CO; Baqar S; Munoz C; Murphy JR
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):535-42. PubMed ID: 2187503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
